|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2200066945 |
|
最近更新日期: Date of Last Refreshed on: |
2022-12-22 08:49:09 |
|
注册时间: Date of Registration: |
2022-12-22 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
社区康复干预对精神分裂症影响的整群随机对照试验 |
|
Public title: |
The impact of community-based rehabilitation interventions on quality of care for people with schizophrenia: A cluster-randomized controlled trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
社区康复干预对精神分裂症影响的整群随机对照试验 |
|
Scientific title: |
The impact of community-based rehabilitation interventions on quality of care for people with schizophrenia: A cluster-randomized controlled trial |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
丁若溪 |
研究负责人: |
朱大伟 |
|
Applicant: |
Ding Ruoxi |
Study leader: |
Zhu Dawei |
|
申请注册联系人电话: Applicant telephone: |
13488810007 |
研究负责人电话:
Study leader's |
13911160537 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
dingruoxi@163.com |
研究负责人电子邮件: Study leader's E-mail: |
phe@pku.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市学院路38号北京大学医学部树华楼 |
研究负责人通讯地址: |
北京市学院路38号北京大学医学部树华楼 |
|
Applicant address: |
Xueyuanlu No.38, Beijing, China |
Study leader's address: |
北京市学院路38号北京大学医学部树华楼 |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
北京大学医学部中国卫生发展研究中心 |
||
|
Applicant's institution: |
China Center for Health and Development Studies, Peking University |
||
|
研究负责人所在单位: |
|
||
|
Affiliation of the Leader: |
|
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
IRB00001052-21170 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
北京大学生物医学伦理委员会 |
||
|
Name of the ethic committee: |
Peking University Institutional Review Board Office |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-03-25 00:00:00 | ||
|
伦理委员会联系人: |
赵励彦 |
||
|
Contact Name of the ethic committee: |
Zhao Liyan |
||
|
伦理委员会联系地址: |
北京市海淀区学院路38号北京大学医学部逸夫楼501 |
||
|
Contact Address of the ethic committee: |
Yifulou 501, Xueyuanlu no.38, Beijing, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
北京大学中国卫生发展研究中心 |
||||||||||||||||||||||
|
Primary sponsor: |
China Center for Health and Development Studies, Peking University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市海淀区学院路38号树华楼 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Xueyuanlu No.38, Beijing, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
美国中华医学基金会 |
||||||||||||||||||||||
|
Source(s) of funding: |
China Medical Board |
||||||||||||||||||||||
|
研究疾病: |
精神分裂症 |
||||||||||||||||||||||
|
Target disease: |
Schizophrenia |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
整群随机分组 |
||||||||||||||||||||||
|
Study design: |
Cluster randomization |
||||||||||||||||||||||
|
研究目的: |
基于北京市海淀区和朝阳区正在推行的社区康复服务规范和国内外干预研究现状,本研究的总目标是通过社区康复干预改善精神分裂症患者的功能,减轻家庭照料负担,并验证社区康复干预是否具有成本效果,探讨其在中国推广的可行性。 具体来说包括两个研究问题: (1)社区康复服务干预是否可以在短期内提高精神分裂症患者治疗依从性和降低入院次数?在长期可以缓解患者疾病症状,改善功能与生命质量以及降低家庭照料负担?为回答这两个问题,本研究将利用影响评价(Impact evaluation,详见研究方法)这一因果推断方法来识别社区康复服务干预对患者及其家庭影响的效应。 (2)如果有影响,精神分裂症患者社区康复干预是否具有成本效果?是否值得推广?为回答这两个问题,本研究将进行干预方案的成本效果与成本效应,并结合我国精神分裂症人群的特点,分析推广干预方案的可行性。 |
||||||||||||||||||||||
|
Objectives of Study: |
The overall goal of the project is to improve quality of care for people with schizophrenia through community-based rehabilitation (CR) intervention. Ultimately, we hope that CR will be cost effective and can be scaled up in China. Objectives of the main study ? To evaluate if the CR intervention will improve adherence to antipsychotic treatment and reduce the hospital readmission rate in persons for schizophrenia (intermediate quality of care outcomes). ? To examine if the CR intervention will reduce symptoms of schizophrenia and improve physical function and quality of life for persons with schizophrenia (long-term quality of care outcomes). ? To analyze the cost-effectiveness of the CR intervention. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1)18-60 岁;2)精神科医生根据ICD-10标准初步诊断为精神分裂症;3)患病时间不少于12个月;4)根据《严重精神障碍管理治疗工作规范》判定为病情稳定的居家患者;5)预期未来4年内居住在研究区域内。 |
||||||||||||||||||||||
|
Inclusion criteria |
The inclusion criteria for participating in the trial are: |
||||||||||||||||||||||
|
排除标准: |
排除患有严重躯体疾病、精神发育迟滞、共病双相情感障碍和重性抑郁障碍的受试者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Ever been diagnosed with drug or alcohol dependence, organic brain disease, learning disability or hearing impairment. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-10-01 00:00:00至 To 2023-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-10-01 00:00:00 至 To 2023-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本研究将按照以下步骤实施: 1)在海淀区和朝阳区各选择5个街道(镇),由社区卫生中心提供社区卫生服务; 2)每个街道(镇)随机抽取10个社区(村), 得到100个社区(村)(2个区*5个街道(镇)*10个社区(村))的样本框; 3)从当地社区的信息系统中获取精神分裂症患者的社会人口特征、健康状况和患病信息; 4)选择两个社区(村), 按照人口数量、年龄、收入、健康状况和精神分裂症患病率进行匹配; 5)确定匹配的两个社区(村)后,将其一随机分配为干预组社区(村);另一组随机分配为对照组社区(村),得到50个干预组社区(村)和50个对照组社区(村); 6)每个社区(村)约有12-15名精神分裂症患者,假设每个社区(村)的招募率为50%,我们从每个社区(村)各招募6名居家患者,共招募600名精神分裂症患者(干预组300名,对照组300名)。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
This study is in the context of the management of people with severe mental illness, which is one of the items of National Basic Public Health Services Program in China. In this program, each person with schizophrenia should be enrolled and managed by the local community (in general by the community |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
https://pan.baidu.com/s/1hro49-UVBBfiaEmcUYtGlw |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
https://pan.baidu.com/s/1hro49-UVBBfiaEmcUYtGlw |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
问卷星、excel. https://pan.baidu.com/s/1hro49-UVBBfiaEmcUYtGlw |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Wenjuanxing Excel https://pan.baidu.com/s/1hro49-UVBBfiaEmcUYtGlw |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |